Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
Status:
Not yet recruiting
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
The interventional, randomized, placebo-controlled, single blind phase II-trial FLORA will
assess safety and immunogenicity of fecal microbiota transfer in combination with standard of
care immunotherapy in advanced hepatocellular carcinoma (HCC) in a parallel group design.
Subjects will be randomized 2:1 into either the FMT or placebo group.
Phase:
Phase 2
Details
Lead Sponsor:
Michael Dill
Collaborators:
German Cancer Research Center Heidelberg University National Center for Tumor Diseases, Heidelberg Universitätsmedizin Mannheim University of Cologne